David M Shackleford Selected Research

David M Shackleford Research Topics

Disease

14	Malaria 11/2021 - 03/2011
10	Neoplasms (Cancer) 01/2022 - 08/2009
4	Chagas Disease (American Trypanosomiasis) 01/2015 - 09/2012
2	Parkinson Disease (Parkinson's Disease) 09/2021 - 01/2017
2	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2020
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2020
2	Parasitemia 01/2021 - 09/2012
2	Cognitive Dysfunction 01/2020 - 11/2016
2	Schizophrenia (Dementia Praecox) 01/2020 - 11/2016
2	Infections 10/2016 - 08/2014
1	Mesothelioma 01/2022
1	Multiple Sclerosis 12/2021
1	Neuroinflammatory Diseases 12/2021
1	Anxiety Disorders (Anxiety Disorder) 01/2021
1	Migraine Disorders (Migraine) 01/2021
1	Cardiotoxicity 01/2021
1	Encephalitis (Encephalitis, Rasmussen) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Memory Disorders (Memory Loss) 01/2020
1	Anhedonia 01/2020
1	Narcolepsy 01/2019
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2018
1	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2017
1	Persistent Infection 10/2016
1	Diabetic Nephropathies (Diabetic Nephropathy) 12/2013
1	Albuminuria 12/2013
1	Fibrosis (Cirrhosis) 12/2013
1	Communicable Diseases (Infectious Diseases) 06/2011
1	Melanoma (Melanoma, Malignant) 02/2010

Drug/Important Bio-Agent (IBA)

12	Pharmaceutical PreparationsIBA 01/2021 - 03/2011
4	Antimalarials (Antimalarial Agents)IBA 11/2021 - 01/2017
3	DSM265IBA 01/2021 - 12/2016
3	Dihydroorotate DehydrogenaseIBA 01/2021 - 12/2016
3	EnzymesIBA 01/2020 - 09/2012
3	benzonidazole (benznidazole)IBA 10/2016 - 09/2012
2	alpha-SynucleinIBA 09/2021 - 01/2017
2	IronIBA 09/2021 - 01/2017
2	8-hydroxyquinazolin-4(3H)-oneIBA 09/2021 - 01/2017
2	1,2,4-trioxaneIBA 01/2021 - 03/2011
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 11/2009
2	NifurtimoxIBA 10/2016 - 01/2015
2	SulfonesIBA 10/2016 - 08/2014
2	fexinidazoleIBA 10/2016 - 08/2014
2	Tubulin ModulatorsIBA 09/2011 - 08/2009
2	CYT997IBA 11/2009 - 08/2009
1	LigandsIBA 01/2022
1	GW 6471IBA 01/2022
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2021
1	c-Mer Tyrosine KinaseIBA 12/2021
1	DiureticsIBA 01/2021
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2021
1	TriazinesIBA 01/2021
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2021
1	Carvedilol (Coreg)FDA LinkGeneric 01/2021
1	5-(N,N-hexamethylene)amilorideIBA 01/2021
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2021
1	Amiloride (Midamor)FDA LinkGeneric 01/2021
1	PyrrolesIBA 01/2020
1	pyrimidineIBA 01/2020
1	Lysine AcetyltransferasesIBA 01/2020
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020
1	Propranolol (Inderal)FDA LinkGeneric 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	CytokinesIBA 01/2020
1	Glutamic Acid (Glutamate)FDA Link 01/2020
1	pitolisantIBA 01/2019
1	artemisinin (artemisinine)IBA 01/2017
1	alpha-aminopyridineIBA 01/2017
1	MMV390048IBA 01/2017
1	Antipsychotic Agents (Antipsychotics)IBA 11/2016
1	SJ733IBA 12/2014
1	sulfoxideIBA 08/2014
1	fenarimolIBA 12/2013
1	3',4'- bis(difluoromethoxycinnamoylanthranilate)IBA 12/2013
1	tranilastIBA 12/2013
1	ethyl 5- ((2,5- dimethyl- 1- (2- (trifluoromethyl)phenyl)pyrrol- 3- yl)methylene)- 2- methyl- 4- oxo- 1H- pyrrole- 3- carboxylateIBA 04/2013
1	6- Chloro- 7- methoxy- 2- methyl- 3- (4- (4- (trifluoromethoxy)phenoxy)phenyl)quinolin- 4(1H)- oneIBA 03/2013
1	SterolsIBA 09/2012
1	AzolesIBA 09/2012
1	posaconazole FDA Link 09/2012
1	tipifarnib (R115777)IBA 09/2012
1	FuransIBA 09/2011
1	BNC 105PIBA 09/2011
1	BNC 105IBA 09/2011
1	EstersIBA 09/2011
1	Phosphates (Orthophosphate)IBA 09/2011
1	benzofuranIBA 09/2011
1	fosbretabulin (combretastatin A4)IBA 09/2011
1	ProdrugsIBA 09/2011
1	GlycosidesIBA 02/2010
1	phosphomannopentaose sulfateIBA 02/2010
1	OligosaccharidesIBA 02/2010

Therapy/Procedure

3	Therapeutics 01/2020 - 06/2011
2	Drug Therapy (Chemotherapy) 02/2021 - 01/2021
1	Aftercare (After-Treatment) 01/2020
1	Withholding Treatment 01/2020
1	Duration of Therapy 10/2016
1	Oral Administration 08/2014